OUR RESEARCH TEAMS
PLATELETS & INFLUENZA: INRA PRESS RELEASE
Platelets play a role in severe pulmonary infections associated with influenza viruses. This has been revealed for the first time by researchers from Team 1 of LVTS in collaboration with researchers from INRA and the Université Claude Bernard Lyon 1. This work has been published on April 1, 2015 in the American Journal of Respiratory and Critical Care Medicine. Their results show that anti-platelet drugs represent an effective therapeutic support against serious influenza.
DIDER LETOURNEUR AT THE FRENCH PARLIAMENT
Over the next five years, a large number of biological drug patents will fall into the public domain. Already, many pharmaceutical companies develop and put on the drug market "Biosimilars" on the same pattern as for the generic chemical drugs. Because substantial savings are expected with this interchangeability, a public audition was held at the French Parliament on 29 January 2015. Didier Letourneur was one the experts that the Committee invited to this session.
MEET ACTICOR BIOTECH TEAM IN PARIS ON JULY 1st, 2014
Some recent news on the Acticor Biotech team, a company dedicated to the development of an innovative, safe and effective treatment of ischemic stroke:
Dr DIDIER LETOURNEUR ON FRANCE 5
Dr GIUSEPPINA CALIGIURI SPOTTED IN THE 'INTERNATIONAL INNOVATION' JOURNAL
The last issue of 'International Innovation', a journal for the global dissemination resource for the wider scientific, technology and research communities, focuses on the Women in Healthcare. Giuseppina (Team 1) has been invited to expose her research and to give her opinion on gender issues in medicine.
Dr DIDIER LETOURNEUR ON BFMTV
ACTICOR SPOTTED IN BIOTECHFINANCES
The agreement between ACTICOR, a biotech hosted within the LVTS and created on the basis of the work from Martine Jandrot-Perrus (Team 1), Christian Gachet (U949) and Philippe Billiad (Institut Paris Sud d'Innovation Thérapeutique) is highlighted in the April issue of the BiotechFinances journal.
Dr DIDIER LETOURNEUR: INNOVATIVE STRATEGY TO FACILITATE ORGAN REPAIR
A significant breakthrough could revolutionize surgical practice and regenerative medicine. The team led by Ludwik Leibler (Laboratoire Matière Molle et Chimie CNRS/ESPCI Paris Tech) and the team headed by Didier Letourneur from the LVTS (INSERM U1148/Universités Paris Diderot and Paris 13), has just demonstrated that the principle of adhesion by aqueous solutions of nanoparticles can be used in vivo to repair soft-tissue organs and tissues. When applied to skin, it closes deep wounds in a few seconds and provides aesthetic, high quality healing. Finally, this solution has s strong potential for delivering drugs and strengthening tissues. This work has just been published on the website of the journal Angewandte Chemie.
FACT: FRENCH ALLIANCE FOR CARDIOVASCULAR TRIALS
The FACT (French Alliance for Cardiovascular Trials) network, chaired by Prof PG Steg (LVTS Team 5) has been selected as an « Investigative Network Initiative » and will receive a 5-year financial support from the F-CRIN (French part of ECRIN - European Clinical Research Infrastructures Network). FACT is an academic research network that federates more than 20 sites throughout France that are interested in doing clinical trials in the field of coronary artery disease, atherothrombosis, and cardiovascular complications of diabetes.
PROF. DOMINIQUE LE GULUDEC APPOINTED CHAIRPERSON OF THE BOARD OF DIRECTORS OF IRSN
PHD in Biophysics, Dominique Le Guludec is Professor of Biophysics and Nuclear Medicine at University Paris 7. She is head of the Department of Nuclear Medicine, Hôpital Bichat, AP-HP, Paris, since 1994. She is also head of a research team of our Inserm Unit 1148, member of the Executive Committee of the EANM, and member of the National Council of Universities (CNU section 4301).
'FUCO-CHEM' COORDINATED BY CÉDRIC CHAUVIERRE SELECTED AS A LABCOM
The 'Agence nationale de la recherche' has selected the first 7 common laboratories between research organisms and private companies as part of the « Labcom » program.
IMMATIS PROJECT LEADED BY DIDIER LETOURNEUR SUPPORTED BY OSEO
For the 15th edition of the National competition for the '’aide à la création d’entreprises de technologies innovantes', the minister of 'Enseignement supérieur et de la Recherche' in association with OSEO has granted 55 projects in the “création-développement” and 120 projects in "Emergence".
NANOATHERO - A NEW FP7 LARGE SCALE PROGRAM COORDINATED BY U698
Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility